| In millions, except per share items | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 | Dec-31-02 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K |
| Revenues: |
| Specialty pharmaceuticals product sales | 403.9 | 303.7 | 326.7 | | | | | |
| U.S. | 357.7 | 223.8 | 244.0 | | | | | |
| Other | 234.9 | 215.2 | 234.4 | | | | | |
| Branded generics — Latin America product sales | 155.2 | 136.6 | 151.3 | | | | | |
| Total revenues | 830.5 | 657.0 | 689.5 | 685.1 | 823.5 | 684.3 | 686.1 | 737.1 |
| Revenue growth [+] | 26.4% | -4.7% | 0.6% | -16.8% | 20.4% | -0.3% | -6.9% | 18.7% |
| Specialty pharmaceuticals product sales | 33.0% | -7.0% | | | | | | |
| U.S. | 59.9% | -8.3% | | | | | | |
| Other | 9.1% | -8.2% | | | | | | |
| Branded generics — Latin America product sales | 13.6% | -9.7% | | | | | | |
| Branded generics — Europe product sales | -0.8% | 22.2% | | | | | | |
| Cost of goods sold | 193.0 | 167.9 | 158.1 | 161.0 | 222.4 | 200.5 | 184.7 | 157.0 |
| Gross profit | 637.5 | 489.1 | 531.4 | 524.0 | 601.2 | 483.7 | 501.4 | 580.1 |
| Gross margin | 76.8% | 74.4% | 77.1% | 76.5% | 73.0% | 70.7% | 73.1% | 78.7% |
| Selling, general and administrative [+] | 255.8 | 278.0 | 292.0 | 283.6 | 340.8 | 296.1 | 278.4 | 530.6 |
| Sales and marketing | | | | | 232.3 | 196.6 | 166.7 | 164.1 |
| General and administrative | | | | | 108.5 | 99.4 | 111.6 | 366.5 |
| Research and development | 44.0 | 87.0 | 98.0 | 105.4 | 114.1 | 92.9 | 45.3 | 49.5 |
| Other operating expenses | 104.9 | 257.6 | 83.7 | 139.9 | 70.1 | 78.6 | 38.6 | 30.7 |
| EBITDA [+] | 319.2 | -67.0 | 129.5 | 65.2 | 173.5 | 103.3 | 203.9 | 23.2 |
| EBITDA growth | -576.3% | -151.8% | 98.7% | -62.4% | 68.0% | -49.4% | 780.5% | -90.6% |
| EBITDA margin | 38.4% | -10.2% | 18.8% | 9.5% | 21.1% | 15.1% | 29.7% | 3.1% |
| Depreciation and amortization | 15.7 | 16.5 | 15.6 | 18.7 | 28.5 | 27.8 | 26.2 | 23.3 |
| EBITA | 303.5 | -83.5 | 113.8 | 46.4 | 145.0 | 75.4 | 177.7 | -0.1 |
| EBITA margin | 36.5% | -12.7% | 16.5% | 6.8% | 17.6% | 11.0% | 25.9% | 0.0% |
| Amortization of intangibles | 70.6 | 50.0 | 56.0 | 51.3 | 68.8 | 59.3 | 38.6 | 30.7 |
| EBIT [+] | 232.8 | -133.5 | 57.8 | -4.9 | 76.1 | 16.1 | 139.1 | -30.8 |
| EBIT growth | -274.4% | -330.9% | -1287.6% | -106.4% | 372.4% | -88.4% | -552.1% | -115.8% |
| EBIT margin | 28.0% | -20.3% | 8.4% | -0.7% | 9.2% | 2.4% | 20.3% | -4.2% |
| Non-recurring items | | | | -51.6 | 126.4 | 11.8 | 117.6 | |
| Interest expense, net [+] | 39.3 | 28.3 | 39.3 | 31.1 | 27.2 | 36.8 | 27.3 | 37.2 |
| Interest expense | 43.6 | 45.4 | 56.9 | 43.5 | 40.3 | 49.3 | 36.1 | 42.9 |
| Interest income | 4.3 | 17.1 | 17.6 | 12.4 | 13.2 | 12.4 | 8.9 | 5.6 |
| Other income (expense), net | 5.8 | -10.9 | 1.7 | 0.8 | -6.4 | -19.8 | -8.1 | 244.9 |
| Pre-tax income | 199.3 | -172.7 | 20.1 | 16.3 | -83.8 | -52.2 | -13.9 | 176.9 |
| Income taxes | -58.3 | 34.7 | 13.5 | 36.6 | 55.1 | 68.6 | 41.2 | 75.0 |
| Tax rate | | | 67.2% | 223.8% | | | | 42.4% |
| Minority interest | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.2 | 11.8 | 17.7 |
| Earnings from continuing ops | 257.6 | -207.4 | 6.6 | -20.2 | -139.1 | -121.1 | -66.9 | 84.2 |
| Earnings from discontinued ops | 6.1 | 166.5 | -26.8 | -37.3 | | | | |
| Net income | 263.7 | -40.8 | -20.2 | -57.6 | -188.7 | -154.7 | -57.5 | -134.8 |
| Net margin | 31.8% | -6.2% | -2.9% | -8.4% | -22.9% | -22.6% | -8.4% | -18.3% |
| |
| Basic EPS [+] | | | | ($0.22) | ($1.52) | ($1.44) | ($0.80) | $1.01 |
| Growth | | | | -85.7% | 5.4% | 79.6% | -179.3% | 7.2% |
| Diluted EPS [+] | | | | ($0.22) | ($1.52) | ($1.44) | ($0.80) | $1.00 |
| Growth | | | | -85.7% | 5.4% | 79.6% | -180.0% | 9.0% |
| |
| Shares outstanding (basic) [+] | | | | 92.9 | 91.6 | 84.1 | 83.4 | 83.3 |
| Growth | | | | 1.4% | 9.0% | 0.8% | 0.1% | 2.7% |
| Shares outstanding (diluted) [+] | | | | 92.9 | 91.6 | 84.1 | 83.4 | 84.0 |
| Growth | | | | 1.4% | 9.0% | 0.8% | -0.7% | 1.0% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |